Get the Stockscreener App
2.48
6.90%
0.16
Hookipa Pharma Inc Stock (HOOK) Latest News
HOOKIPA Pharma's SWOT analysis: stock faces challenges amid pipeline shifts - Investing.com
HOOK (HOOKIPA Pharma) GF Value Rank : 2 (As of Nov. 25, 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) Debt-to-Equity : 0.04 (As of Sep. 2024) - GuruFocus.com
JMP Securities Has Lowered Expectations for Hookipa Pharma (NASDAQ:HOOK) Stock Price - Defense World
Hookipa Pharma price target lowered to $7 from $24 at JMP Securities - Yahoo Finance
Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program - Yahoo Finance
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges - Investing.com
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky - Simply Wall St
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
HOOKIPA Pharma stock target lowered, maintains outlook on strategic direction - Investing.com
RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target - Quantisnow
HOOKIPA Pharma Inc (HOOK) Quarterly 10-Q Report - Quartzy
Hookipa Pharma stock hits 52-week low at $3.4 amid market challenges - Investing.com Australia
Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes - TipRanks
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates - The Bakersfield Californian
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - Quantisnow
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker - Yahoo Finance
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com - Investing.com UK
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - Quantisnow
HOOKIPA commences HPV16+ cancer adjuvant care trial - Investing.com India
HOOKIPA commences HPV16+ cancer adjuvant care trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - The Manila Times
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator - The Bakersfield Californian
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges - Investing.com
Hookipa Pharma stock hits 52-week low at $4.06 amid market challenges - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in cancer immunotherapy - Investing.com
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
HOOKIPA presents KRAS cancer treatment data By Investing.com - Investing.com South Africa
HOOKIPA presents KRAS cancer treatment data - Investing.com India
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset - Marketscreener.com
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight - GlobeNewswire Inc.
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm | FinancialContent Business Page - Financial Content
How To Trade (HOOK) - Stock Traders Daily
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet - MSN
HOOKIPA appoints new Non-Executive Chair as two members exit - Investing.com India
HOOKIPA appoints new Non-Executive Chair as two members exit By Investing.com - Investing.com South Africa
HOOKIPA Pharma Announces Board of Directors Changes - citybiz
Hookipa Pharma Announces Board Restructuring and Appointments - TipRanks
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):